Granocyte (Lenograstim)

Granocyte is prescribed to help patients whose neutrophil counts are reduced due to specific medical conditions or treatments.

• Chemotherapy‑induced neutropenia in adult cancer patients.
• Neutropenia following allogeneic bone‑marrow or stem‑cell transplantation.
• Severe chronic neutropenia of congenital or acquired origin.
• Supportive care to reduce infection risk during intensive myelosuppressive therapy.
• Off‑label use may be considered in clinical trials under physician supervision.

Granocyte can cause a range of adverse reactions, most of which are mild to moderate, while rare events may be serious.

Common

• Bone pain, especially in the lower back or limbs.
• Injection‑site reactions such as redness, swelling, or tenderness.
• Fever, chills, or flu‑like symptoms shortly after dosing.
• Nausea, vomiting, or mild gastrointestinal discomfort.

Serious

• Splenic rupture or enlargement leading to abdominal pain.
• Acute respiratory distress or severe allergic reactions (anaphylaxis).
• Development of leukocytosis with excessively high white‑blood‑cell counts.
• Capillary leak syndrome presenting with hypotension and edema.

Before initiating Granocyte, clinicians should evaluate patient history and monitor specific parameters to minimize risks.

• Assess baseline neutrophil count and overall bone‑marrow function.
• Screen for hypersensitivity to recombinant proteins or excipients.
• Use caution in patients with a history of splenic disorders or trauma.
• Monitor for signs of leukocytosis or abnormal white‑blood‑cell proliferation.
• Adjust dosing in renal or hepatic impairment as per clinical judgment.
• Avoid use in patients with active uncontrolled infections.

Granocyte may interact with other agents that affect the immune system or hematologic parameters.

Avoid

• Concurrent use of other granulocyte colony‑stimulating factors (e.g., filgrastim, pegfilgrastim) due to overlapping mechanisms.
• High‑dose corticosteroids that may blunt neutrophil response.
• Chemotherapeutic agents that cause profound myelosuppression when administered simultaneously without appropriate timing.

Use with caution

• Anticoagulants, as rapid neutrophil recovery can influence coagulation status.
• Immunosuppressive biologics (e.g., rituximab) that may alter infection risk.
• Vaccines, particularly live attenuated vaccines, due to potential altered immune response.